A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL)-Reference-Cited by-同舟云学术

A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL)

Published:2022-10-17 Issue:6 Volume:90 Page:445-453
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Johnson Suja,Dhamne Chetan,Sankaran Hari,Gandhi Khushboo A.,Rane Pallavi,Moulik Nirmaly Roy,Jadhav Shraddha Mahesh,Gurjar Murari,Narula Gaurav,Banavali Shripad,Gota Vikram^ORCID

Funder

ImPaCCT Foundation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-022-04482-8.pdf

Reference31 articles.

1. Egler RA, Ahuja SP, Matloub Y (2016) L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother 7:62–71. https://doi.org/10.4103/0976-500X.184769

2. Avramis VI, Tiwari PN (2006) Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine 1:241

3. Avramis VI, Panosyan EH (2005) Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 44:367–393. https://doi.org/10.2165/00003088-200544040-00003

4. Métayer LE, Brown RD, Carlebur S et al (2019) Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts. Apoptosis 24:145–156. https://doi.org/10.1007/S10495-018-1506-3/FIGURES/7

5. Radadiya A, Zhu W, Coricello A et al (2020) Improving the treatment of acute lymphoblastic leukemia. Biochemistry 59:3193–3200. https://doi.org/10.1021/ACS.BIOCHEM.0C00354